NEWSROOM

Discover the latest news about Medison

PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]

PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]

PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]

PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]

PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]

PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]

PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

PBS listing for Australians with unresectable or metastatic uveal melanoma

Always Ahead

Linkedin-in
© Copyright 2025 © Medison Pharma. All Rights Reserved.